# Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

> **NCT00993668** · PHASE4 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 224 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** Certolizumab pegol

## Key facts

- **NCT ID:** NCT00993668
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-06
- **Final completion:** 2011-02
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2018-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00993668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00993668, "Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00993668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*